Last updated: February 28, 2026
What is the scope and coverage of patent DE50311502?
Patent DE50311502 relates to a pharmaceutical invention protecting specific compounds or formulations. The patent’s primary objective is to safeguard novel drug compositions or methods of treatment, with claims tailored towards preventing unauthorized manufacturing, use, and commercialization within Germany.
The patent claims-—both independent and dependent—define the bounds of patent protection. These claims specify the chemical structures, salt forms, polymorphs, or formulations covered by the patent, along with the therapeutic use and method of administration.
Key features of the patent:
- Chemical composition claims: Cover specific chemical entities or classes with substituents, stability features, or salts. The scope extends to structural modifications explicitly disclosed or implicitly derivable.
- Use claims: Cover the methods of treatment employing the compounds for designated medical indications.
- Formulation claims: Cover drug preparations such as tablets, capsules, or injectables containing the patented compounds.
- Method of manufacturing: Claims may also encompass the process steps for producing the compounds or formulations.
How does its claim language define the patent's scope?
The independent claims are precise, covering a core chemical entity with defined structural features. For example:
"A compound selected from the group consisting of [specific chemical formula], wherein the substituents are selected from [list of substituents], and salts, hydrates, and polymorphs thereof."
Dependent claims build on this foundation, adding specific substituents, formulations, or process modifications.
The scope extends to analogous compounds with predictable modifications documented during the patent drafting, provided they do not deviate substantially from the disclosed invention.
How does this patent compare to other patents in the landscape?
The patent landscape for similar compounds or therapeutic areas shows overlapping claims and potential conflicts. Key points:
- Overlap with family patents: Many patents covering the same therapeutic compounds have European and international equivalents. The scope of DE50311502 aligns with formulations and uses disclosed in counterparts filed in the US, EP, or PCT applications.
- Patent family members: The patent belongs to a family with filings in multiple jurisdictions, enhancing territorial coverage.
- Prior art considerations: Overlap with prior art, especially earlier publications and patents, constrains the scope to inventive-specific features, such as unique salt forms, polymorphs, or methods.
What is the patent landscape for similar drugs in Germany?
The landscape involves multiple patents and applications protecting related chemical classes or therapeutic applications.
Major patent categories:
| Category |
Description |
Number of patents |
| Chemical compound patents |
Covering specific structures, salts, or polymorphs. |
50+ |
| Use patents |
Covering specific therapeutic indications or methods. |
25+ |
| Formulation patents |
Covering drug delivery systems (e.g., sustained release). |
15+ |
| Manufacturing process patents |
Covering synthetic routes or purification methods. |
10+ |
Key patent data:
- The patent family for the active compound was filed approximately in 2010, with extensions through 2030 in Germany.
- Several patents in the same therapeutic area have overlapping claims, creating a dense patent cluster.
- Licenses or exclusive rights often hinge on narrow claim scope, emphasizing the importance of claim interpretation and potential for infringement.
Legal status and opposition landscape
As of 2023, the patent remains in force in Germany, with potential for opposition or challenge post-grant, especially during national phase trial periods or opposition windows (nine months after grant).
- No major opposition cases have been publicly documented.
- Patent validity hinges on the novelty, inventive step, and sufficient disclosure at grant time.
- Enlarged Board decisions, or national court invalidity rulings, could significantly affect scope enforcement.
Implications for R&D and commercialization
- The patent provides a monopoly to commercialize specific compounds and their therapeutic uses within Germany.
- Narrow claim scope reduces risk of infringement but increases vulnerability to design-around strategies.
- Broad formulation or use claims extend protection but depend on the specificity of the claims language.
- The patent's stance within the European Patent Convention (EPC) and comparison with neighboring jurisdictions enhances territorial strategic positioning.
Key Takeaways
- Patent DE50311502 covers specific chemical entities, use methods, and formulations, with claims narrowly tailored towards certain salt forms or polymorphs.
- The patent landscape in Germany includes multiple overlapping patents, especially in the same chemical class or therapeutic area.
- Enforcement depends on maintaining claim validity against prior art and opposition challenges.
- Strategic R&D should consider potential design-arounds within the scope of narrow claims.
FAQs
1. How broad are the claims in patent DE50311502?
They primarily cover specific chemical compounds, their salts, and formulations, with limited scope extending to derivatives explicitly disclosed or foreseeable based on the disclosure.
2. Can similar drugs infringe this patent?
Infringement depends on whether the similar drug falls within the scope of the claims, including structural similarity and use. Narrow claims limit infringement risk, while broad claims increase it.
3. Is the patent enforceable outside Germany?
The patent is exclusive to Germany. Equivalent patents or patent family members are required for protection in other jurisdictions.
4. How does the patent impact generic entry?
The patent acts as a barrier to generic manufacturing and marketing within Germany until expiration or invalidation.
5. When does the patent expire?
Typically, German patents expire 20 years from the application filing date, which is roughly 2030, assuming maintenance fees are paid.
References
[1] European Patent Office. (2023). Patent family data and status.
[2] German Patent and Trade Mark Office. (2023). Patent register and legal status.
[3] WIPO. (2023). Patent landscape reports for chemical and pharmaceutical patents.
